It might be quicker than you'd think.
New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound after stopping GLP-1 medications.
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results